Suppr超能文献

粪肠球菌FK-23口服给药揭示常年性变应性鼻炎中结核菌素反应与临床表现之间的负相关:一项初步研究。

Lysed enterococcus faecalis FK-23 oral administration reveals inverse association between tuberculin responses and clinical manifestations in perennial allergic rhinitis: a pilot study.

作者信息

Shimada T, Cheng L, Enomoto T, Yang X, Miyoshi A, Shirakawa T

机构信息

Central Research Laboratories, Nichinichi Pharmaceutical Co., Ltd., Mie, Japan.

出版信息

J Investig Allergol Clin Immunol. 2004;14(3):187-92.

Abstract

BACKGROUND

The interest in anti-allergy immunoregulation by lactic acid bacteria (LAB) has been growing over the last few decades. There is evidence to suggest that lysed Enterococcus faecalis FK-23 (LFK), a kind of LAB preparation, could relieve the clinical symptoms of Japanese cedar pollinosis. However, little is known about how LFK plays a role in combating allergy.

OBJECTIVE

The aim of this study was to clarify whether improvement of clinical manifestations is associated with enhancement of tuberculin responses in patients with allergic rhinitis treated by LFK.

METHODS

One gram of LFK per day was administered orally to fifty perennial allergic rhinitis patients in an open trial that lasted 28 days. Nasal symptoms and sign scores were rated before and after administration of LFK. Tuberculin responses and peripheral blood cells were also measured before and after LFK treatment.

RESULTS

Purified protein derivative (PPD) skin test diameter was 2.14 +/- 2.14 mm before LFK administration versus 7.26 +/- 4.81 mm at day 31 (p < 0.01). A significant inverse correlation was recognized between PPD skin test diameters and total nasal scores in the nasal provocation test before and after treatment (r= - 0.600, p < 0.001). Peripheral blood eosinophils were 248 +/- 149 cells/ml before LFK administration and then they significantly decreased to 76 +/- 98 cells/microl (p < 0.01).

CONCLUSIONS

These finding may be interpreted as a result of improved clinical symptoms in allergic rhinitis after LFK oral treatment owing to the enhanced host's Th1-type immune responses and supression of the over-expression of Th2-dominated allergic responses.

摘要

背景

在过去几十年中,乳酸菌(LAB)对抗过敏免疫调节的作用日益受到关注。有证据表明,一种乳酸菌制剂——溶壁粪肠球菌FK-23(LFK),可以缓解日本雪松花粉症的临床症状。然而,关于LFK如何对抗过敏作用的了解甚少。

目的

本研究旨在阐明在接受LFK治疗的变应性鼻炎患者中,临床表现的改善是否与结核菌素反应增强相关。

方法

在一项为期28天的开放试验中,对50例常年性变应性鼻炎患者每天口服1克LFK。在服用LFK前后对鼻部症状和体征进行评分。同时在LFK治疗前后测量结核菌素反应和外周血细胞。

结果

服用LFK前纯化蛋白衍生物(PPD)皮肤试验直径为2.14±2.14毫米,在第31天时为7.26±4.81毫米(p<0.01)。在治疗前后的鼻激发试验中,PPD皮肤试验直径与总鼻部分数之间存在显著的负相关(r=-0.600,p<0.001)。服用LFK前外周血嗜酸性粒细胞为248±149个/毫升,之后显著降至76±98个/微升(p<0.01)。

结论

这些发现可能被解释为,LFK口服治疗后变应性鼻炎临床症状改善是由于宿主Th1型免疫反应增强以及Th2主导的过敏反应过度表达受到抑制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验